Should I Buy IRD? IRD 2026 Analysis

Should You Buy Opus Genetics Inc (IRD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

2.310

1 Day change

-7.60%

52 Week Range

3.050

Analysis Updated At

2026/01/29

BUY now. Even after today’s -7.41% drop to 2.49, the broader trend setup remains constructive (bullish moving-average stack) and sentiment from both insiders and hedge funds is strongly positive. With no negative news flow in the past week and analysts initiating with high upside targets ($7–$9), IRD offers an attractive “buy-now” entry for an impatient investor, using 2.13 (S1 support) as the key technical line that must hold.

Technical Analysis

Price/Trend: IRD closed at 2.49 (below the 2.517 pivot), after a sharp one-day pullback (-7.41%). Despite the dip, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which generally indicates an uptrend structure is still intact. Momentum: MACD histogram is positive (0.0525) but contracting—bullish momentum is fading short-term, consistent with the pullback. RSI: RSI(6) at 51.3 is neutral, suggesting neither overbought nor oversold. Key levels: Immediate resistance is 2.906 (R1) then 3.147 (R2). Support is 2.127 (S1) then 1.886 (S2). With price slightly under the pivot, the clean technical thesis is: buy here for a rebound, but the trade is weakened if it loses 2.13. Pattern-based short-term odds: Similar-pattern projection shows modest expected drift (next day ~0.12%, week ~0.42%, month ~0.83%), implying no strong statistical edge—so the bullish case leans more on positioning/sentiment and the trend structure than on near-term pattern alpha. Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call ratio at 0.06 is extremely call-heavy (bullish positioning). However, same-day option volume put/call ratio at 8.5 is bearish on the day (puts dominated volume), which likely reflects short-term hedging/fear after the sharp selloff. Activity: Total options volume is small (19 contracts) but is far above its 30-day average (21.59x), suggesting a sudden sentiment/hedging burst rather than steady flow. Volatility: 30D IV ~63.8% vs historical vol ~72.35%. IV percentile/rank at 0 implies IV is at the low end of its recent range (options not priced for large moves), which can be supportive for buyers expecting catalysts (but the internal IV averages shown are inconsistent with the 30D IV, so treat the “very low IV” read as directional rather than precise).

Technical Summary

Sell

Buy

Positive Catalysts

Analyst support with large implied upside: Piper Sandler Overweight ($7 PT) and B. Riley Buy ($9 PT), both recent initiations.
Smart-money behavior: Hedge funds are reported as buying aggressively (+2167.49% QoQ), and insiders are buying (+231.65% MoM), a strong positive sentiment signal.
Upcoming catalyst window: Next earnings (QDEC
on 2026-02-11 pre-market; biotech names can re-rate into catalyst events.
Pipeline narrative remains intact per analyst notes (lead gene therapy OPGx-LCA5 and program OPGx-BEST1).

Neutral/Negative Catalysts

Near-term technical damage: A -7.41% down day and close below the pivot (2.
increases the chance of testing 2.13 support.
Options tape mixed-to-bearish on the day: put-heavy volume suggests traders may be hedging or speculating on further downside.
Fundamentals still loss-making: EPS remains negative and revenue declined YoY, which can pressure sentiment without clear clinical/earnings catalysts.
No supportive news in the past week to explain/offset the selloff; absent a headline, weak tape can persist short-term.

Financial Performance

Latest reported quarter: 2025/Q3. - Revenue: 3.079M, down -20.38% YoY (top-line contraction). - Net income: -17.454M, improved 131.92% YoY (loss narrowed vs prior year). - EPS: -0.25, down -13.79% YoY (worse per-share loss despite net income improvement, likely due to share count/other factors). - Gross margin: 100% (typical for certain biotech/revenue mix; not the key driver vs cash burn and trial progress). Overall: Financial trend is “still pre-profit biotech,” with some improvement in net loss but weakening revenue and still-negative EPS—price action will be driven more by pipeline progress/financing expectations than by classic operating leverage.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Fresh initiations are bullish. - 2025-11-25: Piper Sandler initiated at Overweight with a $7 PT, highlighting early efficacy data for OPGx-LCA5 and promising preclinical data for OPGx-BEST1. - 2025-12-09: B. Riley initiated at Buy with a $9 PT. Wall Street pro view (pros/cons): Pros: High unmet-need indication, encouraging early/preclinical data narrative, and large upside implied by PTs versus current ~$2.5. Cons: Early-stage biotech execution risk, cash burn/financing overhang typical for the space, and revenue/EPS trends not yet demonstrating durable operating strength. Influential/political trading: No recent congress trading data available in the last 90 days, and no politician/influential figure transactions were provided here.

9 Analyst Rating

Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8 USD with a low forecast of 6 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.500

Low

Averages

High

Current: 2.500

Low

Averages

High

B. Riley

NULL -> Buy

initiated

AI Analysis

2025-12-09

Reason

B. Riley

Price Target

AI Analysis

2025-12-09

initiated

NULL -> Buy

Reason

B. Riley initiated coverage of Opus Genetics with a Buy rating and $9 price target.

Piper Sandler

Overweight

initiated

2025-11-25

Reason

Piper Sandler

Price Target

2025-11-25

initiated

Overweight

Reason

Piper Sandler initiated coverage of Opus Genetics with an Overweight rating and $7 price target. The company has demonstrated early efficacy data for its lead gene therapy program, OPGx-LCA5, in Leber congenital amaurosis type 5, where there are currently no treatment options and a high unmet need, the analyst tells investors in a research note. In addition, Piper says Opus' second gene therapy program, OPGx-BEST1 for BEST1-related inherited retinal diseases, has promising preclinical data.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IRD

Unlock Now

IRD Should I Buy

IRD Should I Buy

Should You Buy Opus Genetics Inc (IRD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch